Zevra Therapeutics 미래 성장

Future 기준 확인 6/6

Zevra Therapeutics (는) 각각 연간 73.5% 및 50.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 72.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 81.4% 로 예상됩니다.

주요 정보

73.5%

수익 성장률

72.9%

EPS 성장률

Pharmaceuticals 수익 성장	23.9%
매출 성장률	50.3%
향후 자기자본 수익률	81.4%
애널리스트 커버리지	Good
마지막 업데이트	25 Nov 2024

최근 미래 성장 업데이트

Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results

Nov 15

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates

Apr 04

Recent updates

Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results

Nov 15

Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%

Aug 30

Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors

Jul 12

Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically

Apr 07

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates

Apr 04

Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors

Apr 02

Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects

Dec 28

Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts

Sep 05

This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year

Aug 20

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable

Apr 17

US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results

Mar 10

Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?

Mar 08

Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates

Nov 16

Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?

Nov 11

KemPharm posts Phase 1 data to support further studies for sleep disorder therapy

Sep 28

KemPharm wins Buy rating at Canaccord on CNS focus

Sep 15

수익 및 매출 성장 예측

NasdaqGS:ZVRA - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	171	42	39	37	7
12/31/2025	98	-12	-28	-27	8
12/31/2024	20	-90	-59	-54	8
9/30/2024	24	-90	-70	-70	N/A
6/30/2024	24	-67	-56	-56	N/A
3/31/2024	28	-49	-46	-46	N/A
12/31/2023	27	-46	-34	-34	N/A
9/30/2023	17	-20	-22	-22	N/A
6/30/2023	17	-17	-24	-24	N/A
3/31/2023	9	-38	-19	-19	N/A
12/31/2022	10	-27	-19	-19	N/A
9/30/2022	11	-35	-15	-15	N/A
6/30/2022	10	-30	-11	-11	N/A
3/31/2022	20	-17	9	9	N/A
12/31/2021	29	-63	10	10	N/A
9/30/2021	28	-65	10	10	N/A
6/30/2021	28	-66	12	12	N/A
3/31/2021	23	-55	-3	-3	N/A
12/31/2020	13	-13	-2	-2	N/A
9/30/2020	12	-14	-4	-4	N/A
6/30/2020	22	-8	-5	-5	N/A
3/31/2020	15	-18	-15	-15	N/A
12/31/2019	13	-25	-24	-24	N/A
9/30/2019	11	-24	-36	-36	N/A
6/30/2019	N/A	-42	-49	-49	N/A
3/31/2019	N/A	-43	-51	-51	N/A
12/31/2018	N/A	-56	-54	-54	N/A
9/30/2018	N/A	-62	-46	-46	N/A
6/30/2018	N/A	-57	N/A	-40	N/A
3/31/2018	N/A	-53	N/A	-38	N/A
12/31/2017	N/A	-43	N/A	-33	N/A
9/30/2017	N/A	-43	N/A	-36	N/A
6/30/2017	N/A	-45	N/A	-34	N/A
3/31/2017	N/A	-30	N/A	-35	N/A
12/31/2016	N/A	-17	N/A	-30	N/A
9/30/2016	N/A	-16	N/A	-27	N/A
6/30/2016	N/A	-13	N/A	-23	N/A
3/31/2016	N/A	-52	N/A	-20	N/A
12/31/2015	N/A	-55	N/A	-20	N/A
9/30/2015	N/A	-57	N/A	-21	N/A
6/30/2015	N/A	-55	N/A	-20	N/A
3/31/2015	N/A	-29	N/A	-18	N/A
12/31/2014	N/A	-24	N/A	-15	N/A
9/30/2014	N/A	-14	N/A	-9	N/A

애널리스트 미래 성장 예측

수입 대 저축률: ZVRA 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.6% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: ZVRA (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: ZVRA 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: ZVRA 의 수익(연간 50.3% ) US 시장( 9.1% 보다 빠르게 성장할 것으로 예상됩니다. 9.1% 연간).

고성장 수익: ZVRA 의 수익(연간 50.3% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: ZVRA 의 자본 수익률은 3년 내에 매우 높을 것으로 예상됩니다( 81.4 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/23 12:16
장 마감 주가	2024/12/23 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Zevra Therapeutics, Inc. 16 애널리스트 중 8 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Dewey Steadman	Canaccord Genuity
Sumant Satchidanand Kulkarni	Canaccord Genuity
Louise Chen	Cantor Fitzgerald & Co.

Zevra Therapeutics 미래 성장

Future 기준 확인 6/6

주요 정보

최근 미래 성장 업데이트

Consensus revenue estimates fall by 14%

Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results

Price target increased by 14% to US$20.50

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates

Price target decreased by 9.1% to US$17.50

Consensus EPS estimates fall by 50%

Recent updates

Zevra Therapeutics, Inc. Announces Departure of Executives

Zevra Therapeutics, Inc. Announces U.S. Commercial Availability of MIPLYFFA for Treatment of Niemann-Pick Disease Type C

Consensus revenue estimates fall by 14%

Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Zevra Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Price target increased by 14% to US$20.50

Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Zevra Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $60.000005 million.

New major risk - Shareholder dilution

Zevra Therapeutics, Inc. Announces FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

New minor risk - Share price stability

Zevra Therapeutics, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Independent Director recently bought US$59k worth of stock

Zevra Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors

Zevra Therapeutics, Inc. Expands Executive Leadership Team

Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of Kp1077 for Idiopathic Hypersomnia At Sleep 2024 Annual Meeting

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Zevra Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically

Zevra Therapeutics, Inc., Annual General Meeting, May 13, 2024

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates

Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors

Price target decreased by 9.1% to US$17.50

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 50%

Zevra Therapeutics, Inc. Announces Top-Line Data from the Phase 2 Clinical Trial of Kp1077 for Idiopathic Hypersomnia

Zevra Therapeutics, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Forecast breakeven date pushed back to 2026

Zevra Therapeutics, Inc. Appoints Alvin Shih to the Board of Directors

Zevra Therapeutics, Inc. Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects

Zevra Therapeutics, Inc. Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration

No longer forecast to breakeven

Zevra Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Zevra Therapeutics, Inc. Announces Executive Changes

Zevra Therapeutics, Inc. Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of Sdx, the Sole Active Pharmaceutical Ingredient in Kp1077, in Healthy Volunteers At Psych Congress 2023

Independent Director recently bought US$51k worth of stock

Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts

Consensus revenue estimates increase by 18%

Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) entered into definitive Agreement to acquire Acer Therapeutics Inc. (NasdaqCM:ACER) for $91 million.

Consensus revenue estimates increase by 27%

This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year

No longer forecast to breakeven

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Zevra Therapeutics, Inc. Announces Board Changes

High number of new directors

Consensus revenue estimates fall by 10%

Independent Director recently bought US$50k worth of stock

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Zevra Therapeutics, Inc. Announces Change of CEO, Effective June 1, 2023

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable

Price target decreased by 13% to US$16.80

US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results

Full year 2022 earnings: EPS and revenues miss analyst expectations

Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?

KemPharm, Inc. Appoints Daniel Gallo as Senior Vice President of Medical Affairs and Advocacy

KemPharm, Inc., Annual General Meeting, Apr 25, 2023

CEO & Director recently bought US$52k worth of stock

KemPharm, Inc. Announces Promotion of Sven Guenther to Chief Scientific Officer and Christal Mickle to Chief Product Development Officer

KemPharm, Inc. Appoints Richard W. Pascoe, as Chief Executive Officer

KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)

KemPharm, Inc. Appoints Christopher Posner as New Independent Director

KemPharm, Inc. Announces That the U.S. Food and Drug Administration (The FDA) Grants the Orphan Drug Designation to Serdexmethylphenidate

Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates

No longer forecast to breakeven

No longer forecast to breakeven